Organogenesis Holdings Business Summary

Organogenesis Holdings Inc. (ORGO) is a leading regenerative medicine company that generates revenue through the development, manufacture, and commercialization of bioengineered products and tissue-based solutions. The company’s operations are categorized into two primary business segments: Advanced Wound Care (AWC), which features flagship living-cell products like Apligraf and Dermagraft for chronic wound management, and Surgical & Sports Medicine (SSM), which offers products such as NuShield and PuraPly for soft tissue repair and surgical barriers. As of early 2026, Organogenesis maintains a dominant market position in the AWC sector by leveraging its proprietary amniotic-tissue portfolio and established reimbursement pathways. Its primary direct competitors include MiMedx Group, Integra LifeSciences, Smith & Nephew, and Vericel, relative to whom Organogenesis differentiates itself through its extensive clinical validation and specialized focus on living-cell technologies. Founded in 1985 as a spin-off from the Massachusetts Institute of Technology (MIT) by tissue-engineering pioneer Dr. Eugene A. Bell, the company is currently led by Gary S. Gillheeney, Sr., who serves as Chairman, President, and CEO. Gillheeney, who has been with the firm since 2002, is supported by Chief Financial Officer David C. Francisco, a former executive at PerkinElmer, and Chief Operating Officer Patrick Bilbo, who oversees regulatory and clinical operations. The leadership team is complemented by a board of directors that includes notable industry figures such as Prathyusha Duraibabu, CFO of Sangamo Therapeutics, and Michele Korfin. Major institutional investors currently backing the company include Norges Bank, Geode Capital Management, and First Light Asset Management.